NUTRACEUTICAL REVIEW · HAND–FOOT SYNDROME
Vitamin B6 is a useful example of why plausible is not the same as proven. For years, pyridoxine was used to try to prevent capecitabine-related hand–foot syndrome: redness, tenderness, burning, swelling or peeling of the palms and soles. The idea sounded reasonable. Randomized trials did not confirm it.
Evidence at a glance
- Studied population: people receiving capecitabine for breast, colorectal and other cancers.
- Studied formulation: oral pyridoxine, commonly 100–200 mg daily in trials.
- Outcome: prevention or delay of moderate-to-severe hand–foot syndrome.
- Result: no statistically significant preventive benefit.
- Safety issue: chronic excess vitamin B6 can itself cause sensory neuropathy.
The clearest trial
In a double-blind phase 3 trial, 210 patients starting single-agent capecitabine were assigned to pyridoxine 200 mg daily or placebo for up to eight cycles. Most had metastatic breast cancer; 29% had colorectal cancer. Grade 2 or worse hand–foot syndrome occurred in 31.4% of the pyridoxine group and 37.1% of the placebo group. That numerical difference was not statistically significant, and time to onset did not differ.
The study stopped before its planned enrollment of 296, which limits precision. But it does not stand alone. A prior randomized trial of 200 mg daily in gastrointestinal cancers and another trial of 100 mg daily also found no prevention. A meta-analysis likewise found no significant reduction in hand–foot syndrome overall or in grade 2 or worse cases. The ESMO dermatologic-toxicity guideline therefore does not recommend pyridoxine for prevention.
Why “it’s only a vitamin” is not enough
The 200 mg daily research dose is far above ordinary nutritional needs and above the U.S. adult tolerable upper intake level of 100 mg daily. The NIH Office of Dietary Supplements notes that prolonged high intake can cause severe sensory neuropathy. That matters when numbness, tingling or burning may already be present from treatment. The research dose describes what investigators tested; it is not a personal recommendation.
Hand–foot syndrome is not something to push through silently. Early reporting gives the oncology team a chance to examine the skin, grade the toxicity and adjust capecitabine if needed. Practical care often includes reducing heat and friction, using comfortable footwear and a bland moisturizer, and following the treatment team’s specific skin-care plan. Dose interruption or reduction may be necessary; that decision belongs to the prescribing team.
Questions for the care team
- Are these symptoms hand–foot syndrome, neuropathy, infection or something else?
- Which moisturizer or topical treatment fits my regimen?
- At what point should capecitabine be held or adjusted?
- Am I already getting vitamin B6 from a multivitamin, energy drink or neuropathy supplement?
- Could any supplement obscure or worsen treatment-related nerve symptoms?
Vitamin B6 does not prevent hand–foot syndrome on the evidence we have, and it has no established role in controlling cancer. Sometimes the most useful integrative review is the one that helps us stop doing something unsupported.
Evidence checked October 6, 2026. Educational review; discuss supplements and treatment side effects with your oncology team. Explore the Missing Script library or visit the podcast—coming soon.
